???? Read the full press release: https://cardiolrx.com/cardiol-therapeutics-ph...-diseases/
ARCHER evaluated CardiolRx™, our oral, anti-inflammatory therapy, in patients with acute myocarditis and preserved left ventricular function.
The presentation will expand on topline findings that showed notable improvements in myocardial extracellular volume and a significant reduction in left ventricular mass — providing the first evidence of structural recovery and reverse remodelling in this patient population.
$CRDL | #CardiolRx #ESC2025 #Myocarditis #ClinicalResearch
@escardio
https://x.com/CardiolRx/status/1986052952373522921